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Abstract
The approval of targeted therapies for metastatic colorectal cancer (mCRC) has led to important improvements in patient 
outcomes. However, it is still necessary to increase individualisation of treatments based on tumour genetic profiles to opti-
mise efficacy, while minimising toxicity. As such, there is currently great focus on the discovery and validation of further 
biomarkers in mCRC, with many new potential prognostic and predictive markers being identified alongside developments 
in patient molecular profiling technologies. Here, we review data for validated and emerging biomarkers impacting treatment 
strategies in mCRC. We completed a structured literature search of the PubMed database to identify relevant publications, 
limiting for English-language publications published between 1 January 2014 and 11 July 2018. In addition, we performed 
a manual search of the key general oncology and CRC-focused congresses to identify abstracts reporting emerging mCRC 
biomarker data, and of ClinicalTrials.gov to identify ongoing clinical trials investigating emerging biomarkers in mCRC 
and/or molecular-guided clinical trials. There is solid evidence supporting the use of BRAF status as a prognostic biomarker 
and DYPD, UGT1A1, RAS, and microsatellite instability as predictive biomarkers in mCRC. There are a number of emerging 
biomarkers that may prove to be clinically relevant in the future to have prognostic (HPP1 methylation), predictive (HER3, 
microRNAs, anti-angiogenic markers, and CRC intrinsic subtypes), or both prognostic and predictive values (HER2, CpG 
island methylator phenotype, tumour mutational load, gene fusions, and consensus molecular subtypes). As such, new 
biomarker-led treatment strategies in addition to anti-epidermal growth factor receptor and anti-angiogenetic treatments 
are being explored. Biomarkers that are not recommended to be tested in clinical practice or are unlikely to be imminently 
clinically relevant for mCRC include thymidylate transferase, ERCC1, PIK3CA, and PTEN. We highlight the clinical utility 
of existing and emerging biomarkers in mCRC and provide recommended treatment strategies according to the biomarker 
status. An update on ongoing molecular-guided clinical trials is also provided.
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Key Points for Decision Makers 
With the approval of therapies that specifically target the 
molecular differences between normal cells and cancer 
cells, there is a strong need to ensure that the most ben-
eficial therapeutic strategies are adopted for each patient.
Therapies can be targeted appropriately by assessing the 
presence of biomarkers.
The biomarker landscape in metastatic colorectal cancer 
is evolving and we provide guidance on which biomark-
ers currently are (DPYD, UGT1A1, RAS, microsatellite 
instability), and may become (BRAF, HER2, consensus 
molecular subtypes, CRC intrinsic subtypes, EGFR, 
HER3, microRNA, anti-angiogenic markers, tumour 
mutational load, gene fusions, CpG island methylator 
phenotype), most relevant for clinical practice.
We recommend treatment strategies according to the 
presence or absence of biomarkers including RAS, MSI, 
BRAF, and HER2 and provide an update on ongoing 
molecular-guided clinical trials, which will further  
individualise therapy for patients with mCRC.
1 Introduction
Colorectal cancer (CRC) is one of the most diagnosed can-
cers worldwide, with 1.84 million estimated new cases in 
2018 [1]. Fluorouracil (5-FU) was the historic standard of 
care for patients with CRC, but the treatment landscape 
has evolved rapidly in the metastatic setting following the 
approval of several targeted therapies, leading to improve-
ments in tumour response rates and patient survival [2]. 
Despite the multitude of treatments available, outcomes and 
toxicity with each regimen can vary markedly from patient 
to patient [3]. Therefore, there is a strong need to identify 
disease and host biomarkers that will ensure the most benefi-
cial therapeutic strategy is adopted for each patient.
Although primary tumour location [right-sided (located 
in the caecum to transverse colon) or left-sided (located 
from the splenic flexure to rectum)] has been identified as a 
surrogate marker for tumour biology [4–6], more accurate 
knowledge of a patient’s tumour profile is needed to better 
personalise treatment. Indeed, in recent years there has been 
a great focus on the development of biomarkers in meta-
static CRC (mCRC) [6–9], all with the aim of improving 
outcomes for patients, including avoiding missed treatment 
opportunities or unnecessary toxicity. These have included 
new diagnostic biomarkers (for disease detection and can-
cer staging or risk stratification), new predictive biomarkers 
(to predict patient response to therapy) and new prognostic 
biomarkers (to assess how the disease is likely to evolve). 
Based on these efforts, testing for some biomarkers is now 
standard practice in the mCRC setting. Newer technolo-
gies such as next-generation sequencing (NGS) and tumour 
panels have highlighted many more potential predictive and 
prognostic markers. While these techniques can provide a 
wealth of information, their application in clinical prac-
tice is not always straightforward [10, 11]. There is a clear 
need for evidence-based recommendations to guide the use 
of validated and emerging biomarkers in clinical practice. 
Here we review the clinical utility of existing and emerging 
biomarkers that are being used or investigated to support 
treatment decisions for patients with mCRC, including those 
who develop acquired resistance to treatment.
2  Methods
We completed a structured literature search to identify rele-
vant publications. The PubMed database (www.ncbi.nlm.nih.
gov/pubme d/) was searched using the following terms and 
restrictions: (“metastatic colorectal cancer”[Title/Abstract] 
OR “mCRC”[Title/Abstract]) AND (“biomarkers”[Title/
Abstract] OR “molecular”[Title/Abstract] OR “molecular 
guided”[Title/Abstract] OR “tumor board”[Title/Abstract]), 
limiting for English-language publications (specifically of 
clinical trials, meta-analyses, observational studies, com-
parative studies, clinical studies, systematic reviews, mul-
ticentre studies, or case reports) published between 1 Janu-
ary 2014 and 11 July 2018. The search produced 519 hits. 
The titles and abstracts of these publications were reviewed 
and the full-text versions of manuscripts reporting emerg-
ing mCRC biomarker data were retrieved and reviewed in 
detail. In addition, we performed a manual search of the key 
general oncology and CRC-focused congresses to identify 
abstracts reporting emerging mCRC biomarker data (pub-
lished between 1 January 2015 and 11 July 2018). We also 
performed a manual search of ClinicalTrials.gov to identify 
ongoing clinical trials investigating emerging biomarkers in 
mCRC and/or molecular-guided clinical trials.
3  Biomarkers and Chemotherapy in mCRC 
Neoadjuvant and adjuvant chemotherapy with fluoropyrimi-
dine-based regimens are beneficial for many patients with 
mCRC, and several markers of chemotherapy sensitivity or 
toxicity have been proposed. Dihydropyrimidine dehydro-
genase (DPD) is an enzyme encoded by the DPYD gene that 
catalyses the inactivation of some fluoropyrimidines, and its 
deficiency is associated with increased chemotherapy-related 
toxicity [12–14]. DPYD allelic variants that are associated 
with severe toxicity include DPYD*2A and A2846T [12, 
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15–17]. Other variants have been identified but their clini-
cal relevance remains to be confirmed [15]. The European 
Society for Medical Oncology (ESMO) guidelines do not 
recommend systematic DPD testing before 5-FU or capecit-
abine administration (Table 1), although testing remains a 
good option, with some groups calling for DPYD genotype- 
and/or phenotype-guided individualised dosing to be a new 
standard of care [3, 17]. Indeed, DPD testing is standard 
practice in some European countries, including France [18]. 
Given that fluoropyrimidine treatment can result in severe 
toxicity in up to 39% of patients [17], DPD testing, which 
is feasible in routine clinical practice, may be of value and 
will probably be extended to other European countries in 
forthcoming years. Other potential markers of toxicity or 
response associated with fluoropyrimidines are yet to be 
validated, including genetic variations in the thymidylate 
synthase gene and microRNA (miRNA)-143 [3, 19]. Poly-
morphisms in the gene encoding UDP glucuronosyltrans-
ferase 1 family, polypeptide A1 (UGT1A1) have also been 
linked with tolerance to chemotherapy [20]. While recent 
data from the PETACC-3 trial confirmed an association 
between UGT1A1*28 genotype and chemotherapy-depend-
ent toxicity, other clinical parameters (including sex, age and 
performance status) were found to be stronger predictors of 
toxicity risk [21]. Further to this, a meta-analysis revealed 
an association between UGT1A1*6 polymorphisms and iri-
notecan-induced toxicity in Asian patients [22]. Patients het-
erozygous for UGT1A1*6 were found to be at increased risk 
for severe neutropenia, while patients who were homozygous 
for UGT1A1*6 were found to be at even higher risk for neu-
tropenia and were also more likely to suffer from severe diar-
rhoea [22]. UGT1A1 genotyping/phenotyping is not recom-
mended as a predictive biomarker in everyday practice, but 
remains an option and should be conducted when UGT1A1 
deficiency is suspected, as indicated by low conjugated bili-
rubin, and when administration of > 180 mg/m2 irinotecan 
is planned (Table 1) [3, 23]. The frequency of UGT1A1*6 
is higher, while the frequency of UGT1A1*28 genotype is 
lower, in Asian versus Caucasian patients [23]. Therefore, 
the Pan-Asian-adapted ESMO consensus guidelines for the 
management of patients with mCRC also recommend that a 
lower irinotecan threshold dose for genotyping may be used 
depending on the prevalence of UGT1A1 polymorphisms 
per country [23].
A number of studies have indicated that the excision 
repair cross-complementation group 1 (ERCC1) protein is 
a possible prognostic biomarker in platinum-based treatment 
of metastatic cancers [7, 24–26]. However, survival out-
comes did not significantly differ in patients with high versus 
low baseline ERCC1 levels who received bevacizumab plus 
mFOLFOX6 (leucovorin [folinic acid], 5-FU, oxaliplatin) 
or FOLFIRI (leucovorin, 5-FU, irinotecan) in the MAVER-
ICC trial, the first prospective study to investigate ERCC1 
as a potential biomarker for oxaliplatin-containing regimens 
in patients with untreated mCRC [27, 28]. It is not recom-
mended as a biomarker in clinical practice (Table 1) [3].
4  Biomarkers and Anti‑EGFR Therapy 
in mCRC 
The development and progression of CRC is influenced by 
epidermal growth factor receptor (EGFR) and its down-
stream signalling pathways (Fig. 1) [29]. Therefore, investi-
gation of predictive and prognostic biomarkers historically 
focused on EGFR expression and subsequently on altera-
tions in the RAS/BRAF/MEK/MAPK and PI3K/PTEN/
AKT pathways. Data from clinical trials demonstrate that 
across all lines of therapy RAS mutations predict a lack of 
response to monoclonal antibodies directed against EGFR 
(panitumumab/cetuximab) and potentially a detrimental 
effect of such therapies when combined with oxaliplatin-
based chemotherapy [30–34]. Effective first- and second-line 
therapies are therefore needed for patients with RAS-mutated 
mCRC. Chemotherapy plus bevacizumab is a standard first-
line therapy for these patients (Fig. 2) [3, 35], but has limita-
tions. Specifically, RAS mutations may be associated with 
lesser benefit from chemotherapy plus bevacizumab com-
pared with RAS wild type (WT) mCRC [36–38], although 
the recent JACCRO CC-11 trial suggests that first-line 
mFOLFOXIRI (leucovorin, 5-FU, oxaliplatin, irinotecan) 
plus bevacizumab is effective for patients with RAS-mutated 
mCRC [39]. Treatment with aflibercept or ramucirumab (in 
combination with FOLFIRI) may be efficacious as second-
line therapies for patients with RAS-mutated mCRC [3, 40]. 
Inhibitors of some mutant forms of RAS, such as KRAS 
G12C, are now entering clinical trials [41, 42].
Testing for RAS mutational status is recommended for 
all patients at the time of mCRC diagnosis (Table 1) [3, 7]. 
Initially only mutations in exon 2 of KRAS (which lead to 
constitutive activation of EGFR) were routinely tested. A 
prospective–retrospective biomarker analysis of the Phase III 
PRIME study reported that the presence of additional RAS 
mutations (KRAS exons 3/4 and NRAS exon 2/3/4) also pre-
dict a lack of response to panitumumab plus FOLFOX [31]. 
This observation was subsequently confirmed by retrospec-
tive and prospective analyses of other trials of anti-EGFR 
therapies [43–48]. These mutations are now tested for in 
extended RAS analysis [49]. As around 20% of KRAS exon 
2 WT tumours harbour a different RAS mutation, extended 
RAS testing has significantly impacted clinical outcomes 
[34]. An NGS-based extended RAS panel has recently been 
clinically validated using formalin-fixed paraffin-embedded 
mCRC tumour samples [10]. Of note however, a recently 
reported prospective study of more than 400 patients dem-
onstrated that testing circulating tumour DNA (ctDNA) for 
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RAS correlated well with tissue assessment, with increased 
accuracy for patients with liver metastases [50]. While still 
not recommended by current guidelines [3, 7], ctDNA test-
ing could therefore potentially replace tissue assessment as 
routine practice in these patients.
Clinical trial data suggest that the mutated BRAF V600E 
is a negative prognostic marker for patients with mCRC and 
may predict resistance to EGFR-antibody therapy, espe-
cially in heavily pre-treated patients [51–53]; the predictive 
value of BRAF V600E mutations in earlier lines of therapy 
is uncertain [54, 55]. A recent meta-analysis of randomised 
controlled trials suggested there was insufficient evidence 
to demonstrate that BRAF V600E mutations are a negative 
predictive marker of response to EGFR inhibitors [56], while 
a second meta-analysis demonstrated that anti-EGFR treat-
ment did not increase progression-free survival (PFS) or 
overall response rate (ORR) in patients with BRAF-mutated 
mCRC [57]. However, the outcomes of these meta-analyses 
are debatable as the analyses included studies with differ-
ent patient populations, lines of therapy, control arms and 
anti-EGFR treatment options. More recently, analysis of the 
VOLFI trial found an impressively increased response rate 
in BRAF-mutated patients receiving first-line panitumumab 
plus a triplet chemotherapy regimen versus triplet chemo-
therapy alone (86% vs 22%), although PFS was comparable 
in the two treatment arms [58]. Of note, the sample size was 
small (n = 16) and a cautious interpretation is warranted [58]. 
On balance, accumulating evidence suggests that anti-EGFR 
therapy may be of interest in patients with BRAF-mutated 
mCRC, if used in earlier rather than later lines of therapy, 
but this is not currently a first-choice therapy in this setting 
(Fig. 2). As demonstrated in a small subgroup analysis of the 
TRIBE study [36], and other patient cohorts [59, 60], FOL-
FOXIRI plus bevacizumab may also be a beneficial first-line 
treatment for these patients and is recommended by ESMO 
guidelines for patients with BRAF-mutated mCRC (Fig. 2) 
[3]. Other vascular endothelial growth factor (VEGF) target-
ing agents may also be efficacious in this patient population. 
Tumour samples were obtained for 482/1226 (39%) patients 
randomised in the VELOUR clinical trial, which demon-
strated that aflibercept in combination with FOLFIRI is a 
beneficial second-line treatment for mCRC [61]. Patients 
with BRAF-mutated mCRC (n = 36) had a larger benefit 
from the addition of aflibercept versus placebo to FOLFIRI 
(median OS 10.3 vs 5.5 months) compared with patients 
with WT BRAF (13.0 vs 12.4 months) [61]. However, the 
difference was not significant [HR 0.49 (95% CI 0.22–1.09), 
p = 0.08], possibly due to the small series of patients [61]. 
Similar results were reported in a biomarker analysis of the 
RAISE trial, where the addition of ramucirumab to FOL-
FIRI provided a non-significant benefit in BRAF-mutated 
tumours [62].
Inhibition of BRAF V600E has been shown to cause rapid 
feedback activation of EGFR, which supports continued 
tumour proliferation [63]. As such, inhibition of EGFR has 
been shown to be strongly synergistic with BRAF V600E 
Table 1  Summary of recommendations for biomarker testing accord-
ing to consensus guidelines for the management of patients with 
mCRC from ESMO and the American Society for Clinical Pathology, 
College of American Pathologists, Association for Molecular Pathol-
ogy, and American Society of Clinical Oncology [3, 7]
5-FU fluorouracil, BRAF B-rapidly accelerated fibrosarcoma, DPD dihydropyrimidine dehydrogenase, DPYD DPD gene, EGFR epidermal 
growth factor receptor, ERCC1 excision repair cross-complementation group 1, ESMO European Society for Medical Oncology, KRAS Kirsten 
rat sarcoma viral oncogene, mCRC metastatic colorectal cancer, MSI microsatellite instability, NRAS neuroblastoma RAS, PIK3CA phosphati-
dylinositol 3-kinase catalytic subunit alpha, PTEN phosphatase and tensin homolog, RAS rat sarcoma, TS thymidylate transferase, UGT1A1 UDP 
glucuronosyltransferase 1 family, polypeptide A1
a Testing is recommended in some European countries [18]
Biomarker Recommendation
DPD (DPYD) Testing before 5-FU or capecitabine administration remains an option but is not routinely recommended in all European 
 countriesa
TS Testing not recommended in clinical practice
UGT1A1 UGT1A1 phenotyping remains an option and should be carried out in patients with a suspicion of UGT1A1 deficiency 
as reflected by low conjugated bilirubin and in patients where an irinotecan dose of > 180 mg/m2 per administration is 
planned
ERCC1 Testing not recommended for treatment decisions, could be included prospectively in clinical trials
RAS (KRAS, NRAS) Mandatory test before treatment with anti-EGFR-targeting antibodies cetuximab or panitumumab
BRAF Test alongside RAS for prognostic role and/or for selection in clinical trials
EGFR Evaluation of EGFR amplification, gene copy number and EGFR ectodomain mutations is not recommended for routine 
patient management outside of a clinical trial setting
PIK3CA Testing not recommended for routine clinical practice outside of a clinical trial setting
PTEN Testing not recommended for routine clinical practice outside of a clinical trial setting
MSI Test for predictive value for the use of immune checkpoint inhibitors (pembrolizumab, nivolumab ± ipilimumab)
The Evolving Biomarker Landscape in mCRC 
inhibition in CRC (Fig. 2) [63]. An open-label Phase I/II 
study demonstrated that the BRAF inhibitor dabrafenib 
plus trametinib (a MEK inhibitor) had activity in patients 
with BRAF V600E mutation-positive mCRC, and patients 
receiving triple therapy (dabrafenib, trametinib and panitu-
mumab) had a numerically improved ORR (21%) compared 
with those receiving panitumumab plus either dabrafenib 
(10%) or trametinib (0%) and had a longer PFS (4.2 vs 3.5 
or 2.6 months) [64, 65]. More recently, in a randomised trial, 
addition of vemurafenib to the combination of cetuximab 
and irinotecan resulted in prolonged PFS [4.4 vs 2.0 months, 
hazard ratio (HR) 0.42, 95% confidence interval (CI) 
0.26–0.66; p < 0.001] and a higher disease control rate (67% 
vs 22%; p < 0.001) compared with cetuximab and irinotecan 
treatment alone in heavily pre-treated patients with BRAF-
mutant mCRC [66]. The combination of encorafenib (BRAF 
inhibitor), binimetinib (MEK inhibitor) and cetuximab is 
being assessed in the BEACON trial and has previously 
shown encouraging clinical activity in BRAF V600E mCRC 
(ORR: 48%) [67]. Of note, extended (non-V600/non-V600E) 
BRAF mutations may have different clinical implications 
compared with BRAF V600E mutations [68, 69]. It is rec-
ommended that BRAF mutation status is assessed alongside 
that of RAS for prognostic assessment and/or selection for 
clinical trials (Table 1) [3, 7]. The predictive potential of 
BRAF mutation status is not yet confirmed.
Regarding the potential of EGFR activation as a bio-
marker, studies have focused on the expression of EGFR 
ligands and EGFR gene copy number. High expression lev-
els of the EGFR ligands amphiregulin (AREG) and epiregu-
lin (EREG) have positive prognostic value and are associated 
with a positive response to anti-EGFR therapy [70–72]. For 
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Fig. 1  Overview of the main EGFR and VEGF angiogenic signal-
ling cascades. Upon EGFR dimerisation and autophosphorylation, 
the RAS/BRAF/MEK and PI3K/PTEN/AKT pathways are induced 
(adapted from [29] under the Creative Commons Attribution License 
CC BY-NC 3.0 [https ://creat iveco mmons .org/licen ses/by-nc/3.0/]). 
Ligand binding to VEGFR-1, VEGFR-2, and VEGFR-3 activates 
a number of processes that drive angiogenesis. AKT AKR mouse 
thymoma, BRAF B-rapidly accelerated fibrosarcoma, EGFR epider-
mal growth factor receptor, ERK extracellular receptor kinase, HER 
human epidermal growth factor, MEK mitogen-activated protein 
kinase, mTOR mammalian target of rapamycin, P phosphorylation, 
PI3K phosphatidylinositol 3-kinase, PIGF phosphatidylinositol-
glycan biosynthesis class F, PTEN phosphatase and tensin homolog, 
RAS rat sarcoma, VEGF vascular endothelial growth factor, VEGFR 
VEGF receptor
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example, in RAS (KRAS and NRAS) WT patients receiving 
anti-EGFR therapy, high AREG and EREG expression cor-
related with better survival outcomes [73–75]. High EGFR 
gene copy number has also been associated with improved 
response to anti-EGFR-targeted therapies [76–78], but clini-
cal use of such a biomarker is limited by the rarity of true 
gene amplification and difficulties in obtaining reproducible 
results by fluorescence in situ hybridisation assessment [79]. 
Evaluation of EGFR ligands, EGFR gene copy number, or 
EGFR protein expression is currently not recommended for 
routine patient management in mCRC (Table 1) [3].
Concerning other components of EGFR downstream 
signalling pathways, contradictory data are reported for the 
prognostic and predictive role of PIK3CA and PTEN muta-
tions in mCRC [80]. As such, according to European and 
US guidelines there is insufficient evidence for their use as 
predictive biomarkers for EGFR-antibody therapy (Table 1) 
[3, 7].
Other promising biomarkers include the receptors HER2 
and HER3 (Table 2). Approximately 5% of mCRC tumours 
are driven by HER2 amplification or mutation, which can 
lead to resistance to EGFR-targeted treatment by activating 
a bypass signalling pathway [81–84]. Although the prog-
nostic role of HER2 remains uncertain, alterations in this 
gene have been associated with poorer survival outcomes 
[81, 85]. There is also a growing interest in HER2 as a 
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Fig. 2  Possible treatment strategies according to biomarker status in 
mCRC. aWhere maximum tumour shrinkage is the goal; further con-
firmatory data are needed. Colours indicate possible treatment strate-
gies for tumours with amplified HER2 (pink), mutant BRAF (green), 
MSI-H (light orange), WT RAS; (yellow) and mutant RAS (orange). 
Grey shading indicates WT/normal expression/MSS with no treat-
ment recommendations. AMP amplified, B binimetinib, Bev bevaci-
zumab, BRAF B-rapidly accelerated fibrosarcoma, Cmab cetuximab, 
CT chemotherapy, D dabrafenib, E encorafenib, EGFR epidermal 
growth factor receptor, FOLFIRI leucovorin, fluorouracil and irinote-
can, FOLFOX leucovorin, fluorouracil and oxaliplatin, FOLFOXIRI 
leucovorin, fluorouracil, irinotecan and oxaliplatin, HER2 human epi-
dermal growth factor 2, Ir irinotecan, L lapatinib, mCRC metastatic 
colorectal cancer, MSI-H microsatellite instability high, MSS micros-
atellite stable, MUT mutant, NORM normal, Pmab panitumumab, Pz 
pertuzumab, RAS rat sarcoma, T trametinib, Tz trastuzumab, V vemu-
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The Evolving Biomarker Landscape in mCRC 
Ta
bl
e 
2 
 Se
lec
ted
 tr
ial
 da
ta 
fo
r e
m
er
gi
ng
 bi
om
ar
ke
rs 
of
 re
sp
on
se
/re
sis
tan
ce
 to
 st
an
da
rd
 tr
ea
tm
en
ts 
in
 m
CR
C 
Be
v b
ev
ac
izu
m
ab
, C
I c
on
fid
en
ce
 in
ter
va
l, 
C
m
ab
 ce
tu
xi
m
ab
, C
T 
ch
em
ot
he
ra
py
, E
G
FR
 ep
id
er
m
al 
gr
ow
th
 fa
cto
r r
ec
ep
to
r, 
FO
LF
IR
I l
eu
co
vo
rin
, fl
uo
ro
ur
ac
il,
 an
d 
iri
no
tec
an
, F
O
LF
O
X 
leu
co
vo
rin
, 
flu
or
ou
ra
cil
, a
nd
 o
xa
lip
lat
in
, H
ER
 h
um
an
 ep
id
er
m
al 
gr
ow
th
 fa
cto
r, 
H
R 
ha
za
rd
 ra
tio
, I
r i
rin
ot
ec
an
, m
C
RC
  m
eta
sta
tic
 co
lo
re
cta
l c
an
ce
r, 
m
iR
NA
 m
icr
oR
NA
, N
A 
no
t a
pp
lic
ab
le,
 N
R 
no
t r
ep
or
ted
, 
O
R 
od
ds
 ra
tio
, O
RR
 ob
jec
tiv
e r
es
po
ns
e r
ate
, O
S o
ve
ra
ll 
su
rv
iv
al,
 P
FS
 pr
og
re
ss
io
n-
fre
e s
ur
vi
va
l, 
Pm
ab
 pa
ni
tu
m
um
ab
Bi
om
ar
ke
r
Re
fer
en
ce
s
No
. o
f 
pa
tie
nt
s
Pr
io
r t
he
ra
py
Tr
ea
tm
en
t
Ke
y fi
nd
in
gs
H
ER
2
[8
3]
13
5
An
ti-
EG
FR
 th
er
ap
y
An
ti-
EG
FR
 th
er
ap
y
M
ed
ian
 P
FS
 in
 pa
tie
nt
s r
ec
eiv
in
g a
nt
i-E
GF
R 
th
er
ap
y w
as
 si
gn
ifi
ca
nt
ly
 
sh
or
ter
 in
 th
os
e w
ith
 am
pl
ifi
ed
 co
m
pa
re
d w
ith
 no
n-
am
pl
ifi
ed
 H
ER
2 
tu
m
ou
rs 
(2
.9 
vs
 8.
1 m
on
th
s, 
HR
 5.
0;
 p 
< 
0.0
00
1)
. T
he
se
 fi
nd
in
gs
 w
er
e 
co
nfi
rm
ed
 in
 a 
se
co
nd
 co
ho
rt:
 m
ed
ian
 P
FS
 2.
8 v
s 9
.3 
m
on
th
s (
HR
 6.
6;
 
p <
 0.
00
01
)
CA
-2
00
8-
00
12
; 
NC
T0
08
53
93
1 [
18
5]
34
CT
, B
ev
Pm
ab
Th
e l
ev
el 
of
 H
ER
2 p
ro
tei
n e
xp
re
ss
io
n w
as
 si
gn
ifi
ca
nt
ly
 as
so
cia
ted
 w
ith
 
re
sis
tan
ce
 to
 P
m
ab
; H
ER
2 w
as
 ov
er
ex
pr
es
se
d i
n 4
/1
1 n
on
-re
sp
on
di
ng
 
an
d 0
/2
1 r
es
po
nd
in
g c
as
es
 (p
 =
 0.
03
5)
H
ER
3
PI
CC
OL
O;
 
IS
RC
TN
93
24
88
76
 [9
1]
30
8
Fl
uo
ro
py
rim
id
in
e ±
 
 ox
ali
pl
ati
n ±
 B
ev
Pm
ab
 +
 Ir
 or
 Ir
 al
on
e
Hi
gh
 H
ER
3 w
as
 pr
ed
ict
ive
 of
 P
m
ab
 be
ne
fit
. I
n p
ati
en
ts 
wi
th
 hi
gh
 H
ER
3 
ex
pr
es
sio
n, 
m
ed
ian
 P
FS
 w
as
 8.
2 m
on
th
s (
Pm
ab
 +
 Ir
) v
s 4
.4 
m
on
th
s 
(Ir
) (
HR
 0.
33
; 9
5%
 C
I 0
.19
–0
.58
; p
 <
 0.
00
1)
. P
ati
en
ts 
wi
th
 lo
w 
HE
R3
 ex
pr
es
sio
n g
ain
ed
 no
 be
ne
fit
 in
 P
FS
: 3
.3 
m
on
th
s (
Pm
ab
 +
 Ir
) v
s 
4.3
 m
on
th
s (
Ir)
 (H
R 
0.9
6;
 95
% 
CI
 0.
67
–1
.38
; p
 =
 0.
84
), 
wi
th
 si
gn
ifi
ca
nt
 
in
ter
ac
tio
n (
p =
 0.
00
2)
. T
he
 bi
na
ry
 m
od
el 
wa
s a
lso
 pr
ed
ict
ive
 fo
r O
S,
 
wi
th
 si
gn
ifi
ca
nt
 in
ter
ac
tio
n (
p =
 0.
01
)
m
iR
-3
1-
3p
[9
7, 
99
]
13
2
FO
LF
OX
/F
OL
FI
RI
/ 
an
ti-
EG
FR
NA
m
iR
-3
1-
3p
 ex
pr
es
sio
n l
ev
el 
wa
s s
ig
ni
fic
an
tly
 as
so
cia
ted
 w
ith
 P
FS
 an
d O
S
In
 on
e s
tu
dy
, s
tat
ist
ica
l m
od
els
 ba
se
d o
n m
iR
NA
 ex
pr
es
sio
n d
isc
rim
in
ate
d 
be
tw
ee
n h
ig
h a
nd
 lo
w 
ris
k o
f p
ro
gr
es
sio
n. 
PF
S 
of
 hi
gh
- a
nd
 lo
w-
ris
k 
pa
tie
nt
s w
as
 9 
an
d 3
5.3
 w
ee
ks
, r
es
pe
cti
ve
ly
 (H
R 
4.1
0, 
95
% 
CI
 1.
3–
13
.2;
 
p =
 0.
01
8)
Ne
w 
EP
OC
 tr
ial
; 
NC
T0
04
82
22
2 [
98
]
14
9
Ad
ju
va
nt
 C
T
Cm
ab
 +
 C
T 
or
 C
T 
alo
ne
M
ed
ian
 P
FS
 fo
r m
id
 or
 hi
gh
 m
iR
-3
1-
3p
 ex
pr
es
sio
n w
as
 sh
or
ter
 in
 th
e 
Cm
ab
 vs
 th
e C
T 
ar
m
 (2
6.7
 vs
 12
.3 
m
on
th
s, 
HR
 2.
28
, 9
5%
 C
I 1
.27
–
4.0
9;
 p 
= 
0.0
06
). 
Lo
w 
m
iR
-3
1-
3p
 ex
pr
es
so
rs 
ha
d s
im
ila
r o
ut
co
m
es
 
irr
es
pe
cti
ve
 of
 tr
ea
tm
en
t (
HR
 1.
06
, 9
5%
 C
I 0
.43
–2
.61
; p
 =
 0.
9)
FI
RE
-3
; N
CT
00
43
39
27
 
[9
9]
34
0
No
 pr
io
r s
ys
tem
ic 
th
er
ap
y
Cm
ab
 +
 FO
LF
IR
I o
r 
Be
v +
 FO
LF
IR
I
Lo
w 
m
iR
-3
1-
3p
 ex
pr
es
so
rs 
ha
d a
 si
gn
ifi
ca
nt
ly
 be
tte
r O
S 
(H
R 
0.6
1, 
95
% 
CI
 0.
41
–0
.88
; p
 <
 0.
01
; m
ed
ian
 O
S:
 39
.4 
vs
 27
.4 
m
on
th
s, 
re
sp
ec
tiv
ely
), 
PF
S 
(H
R 
0.7
4, 
95
% 
CI
 0.
55
–1
.00
, p
 =
 0.
05
; m
ed
ian
 P
FS
: 1
1.8
 vs
 
10
.5 
m
on
th
s) 
an
d O
RR
 (O
R 
4.0
, 9
5%
 C
I 1
.9–
8.2
; p
 <
 0.
01
) w
he
n t
re
ate
d 
wi
th
 F
OL
FI
RI
 pl
us
 C
m
ab
 as
 co
m
pa
re
d t
o F
OL
FI
RI
 +
 B
ev
. m
iR
-3
1-
3p
 
is 
pr
ed
ict
ive
 of
 C
m
ab
 eff
ec
t o
n O
S 
(p
 =
 0.
07
), 
PF
S 
(p
 =
 0.
08
) a
nd
 O
RR
 
(p
 =
 0.
06
)
H
PP
1-
m
et
hy
la
te
d 
fre
e-
ci
rc
ul
at
in
g 
D
NA
AI
O‐
KR
K‐
02
07
; 
NC
T0
09
73
60
9 [
16
1]
46
7
NR
Be
v +
 C
T 
or
 B
ev
 al
on
e 
or
 no
 m
ain
ten
an
ce
Pa
tie
nt
s w
ith
 re
du
ce
d H
PP
1-
m
eth
yl
ate
d f
re
e-
cir
cu
lat
in
g D
NA
 af
ter
 
ad
m
in
ist
ra
tio
n o
f c
om
bi
na
tio
n C
T 
ha
d b
ett
er
 O
S 
co
m
pa
re
d w
ith
 th
os
e 
wi
th
 co
nt
in
ue
d d
ete
cta
bl
e l
ev
els
 of
 H
PP
1-
m
eth
yl
ate
d f
re
e-
cir
cu
lat
in
g 
DN
A 
(p
 <
 0.
00
01
).
 J. Taieb et al.
therapeutic target in mCRC (Fig. 2). Dual HER2 blockade 
with a monoclonal antibody (pertuzumab or trastuzumab) 
and a tyrosine kinase inhibitor (lapatinib) has been shown 
to inhibit tumour growth in patient-derived xenografts of 
HER2-amplified mCRC [86, 87]. Moreover, results from the 
HERACLES-A Phase II trial showed that dual blockade was 
efficacious and well tolerated in HER2-positive KRAS exon 
2 WT mCRC patients refractory to current standard of care 
[88, 89]. HER2-targeted therapy was also effective in the 
Phase IIa MyPathway study that involved 57 patients with 
refractory HER2-amplified/overexpressing CRC treated with 
trastuzumab plus pertuzumab; the ORR was 32% [90]. Inter-
estingly, this study included patients with KRAS-mutated 
CRC, but efficacy of HER2-directed therapy was notably 
higher in those with KRAS-WT tumour status [90].
With respect to HER3, a prospectively planned retrospec-
tive biomarker study of pre-treatment samples from the PIC-
COLO trial showed that patients with RAS WT mCRC and 
high HER3 mRNA expression benefited markedly from pan-
itumumab treatment, whereas those with low HER3 mRNA 
expression did not [91]. There were statistically significant 
biomarker-treatment interactions for both PFS (p = 0.001) 
and OS (p = 0.004) [91].
Some miRNAs have been suggested to predict response 
to anti-EGFR therapy [92–94]. For instance, high-intensity 
levels of the Let-7c/miR-99a/miR-125b signature have been 
associated with longer PFS in KRAS WT patients receiv-
ing such therapy [95]. Low miR-181a expression has also 
been associated with poorer outcomes in KRAS WT patients 
undergoing treatment with EGFR-targeting monoclonal anti-
bodies [93, 95], and upregulation of miR-31-5p has been 
shown to be predictive of shorter PFS in patients with mCRC 
receiving anti-EGFR treatment [92, 96]. Furthermore, a 
number of studies have identified miR-31-3p as a promis-
ing predictive biomarker for anti-EGFR therapy in RAS WT 
mCRC, with therapeutic benefit potentially restricted to 
patients with low miR-31-3p expression [97–99].
Finally, primary tumour location, as a surrogate marker 
for tumour molecular characteristics, is known to affect 
prognosis and treatment outcomes with anti-EGFR therapy. 
Left-sided tumours are more prevalent and associated with 
better prognosis than right-sided tumours [4–6]. Right-sided 
tumours are more frequently associated with mutations in 
BRAF, TGFβR2, and PI3KCA and are microsatellite unstable 
[4, 5, 100]. In contrast, amplification of EGFR and HER2, 
overexpression of EGFR ligands and chromosomal insta-
bility are more common in left- than right-sided tumours 
[4, 5]. In the first-line setting, anti-EGFR treatment com-
bined with chemotherapy appears to be more effective than 
bevacizumab in left-sided RAS WT mCRC [100]. Moreo-
ver, patients with right- versus left-sided tumours benefit 
less from anti-EGFR therapy [100]. In patients with right-
sided tumours, treatment with intensive chemotherapy plus 
bevacizumab may be more appropriate, although anti-EGFR 
therapy remains an option to achieve an objective response 
if cytoreduction is the treatment goal [100]. Furthermore, 
patients with right-sided tumours appear to benefit more 
from immunotherapies due to increased antigenic load, 
although further validation is required [101].
Critically, clinical efficacy of targeted therapy is limited 
by the development of acquired resistance [102]. A compre-
hensive analysis of mechanisms of resistance in plasma from 
a large cohort of patients treated with anti-EGFR therapy 
showed that the emergence of RAS mutations (30%) and 
EGFR extracellular domain (ECD) mutations (25%) were 
the most frequent mechanisms of resistance [103]. The 
dynamics of EGFR ECD mutations differ from the emer-
gence of RAS mutations; patients who experience greater 
and longer responses to anti-EGFR therapy reportedly 
develop EGFR ECD mutations and patients with shorter 
PFS seem more likely to develop RAS mutations [104]. 
Mutations in BRAF, as well as MET and HER2, were also 
detected [103]. Importantly, these biomarkers of resistance 
appear to be heterogeneous and mostly sub-clonal, which 
will potentially limit the efficacy of further lines of therapy 
[103]. Another recent study noted that in patients receiv-
ing anti-EGFR therapy and undergoing resection, some 
patients (19%) gained while others (35%) lost mutations on 
the resection specimen as compared with previous biopsy, 
mainly in RAS, providing further evidence of intra-tumoural 
heterogeneity [105]. RAS mutations (at biopsy or resection) 
were associated with worse response and survival compared 
with tumours that were RAS WT [105]. However, in another 
study, RAS mutations that emerged during panitumumab-
based treatment (detected by plasma analysis of ctDNA) 
were not associated with less favourable outcomes [106]. Of 
note, the emergence of acquired mutations shown to confer 
resistance can be detected in plasma months before morpho-
logical tumour progression [107–109]; the clinical utility of 
assessing emerging mutations requires further validation.
5  Biomarkers and Anti‑angiogenic Therapy 
in mCRC 
The role of angiogenesis in tumourigenesis is shown in 
Fig. 1. Despite the importance of this process in disease 
pathology, not all patients with mCRC derive clinical ben-
efit from anti-angiogenic therapy, highlighting the need for 
biomarkers to ensure treatment is appropriately targeted. 
However, the discovery of universal predictive biomarkers 
for anti-angiogenic therapies is challenging, due to host-
involvement in angiogenesis.
Many factors have been identified as being associated 
with better outcomes in patients treated with anti-angiogenic 
agents, suggesting their potential predictive value, such as 
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the loss of chromosome 18q11.2–q12.1 [110], the transcrip-
tion factor homeobox B9 [111, 112], VEGF-D [113, 114], 
and markers of tumour vasculature immaturity [115]. While 
VEGF-A was found not to be predictive of anti-angiogenic 
treatment efficacy in retrospective and prospective series 
[27, 28], it has been suggested that the VEGF-A splice iso-
forms 165b and 121 may predict response to bevacizumab 
[116, 117]. Low levels of hepatocyte growth factor have also 
been associated with survival benefit from bevacizumab 
treatment [117]. Further, several miRNAs have been iden-
tified as possible biomarkers for anti-angiogenic therapy 
[118]. For example, high miR-664-3p expression was sig-
nificantly predictive of improved outcomes in patients with 
mCRC receiving bevacizumab treatment plus chemotherapy 
compared with those receiving chemotherapy alone [119]. 
However, none of these potential biomarkers have acquired 
sufficient evidence to recommend their use in daily practice 
and their clinical utility needs to be confirmed in large pro-
spective trials.
6  Microsatellite Instability/Deficient 
Mismatch Repair Disease
Microsatellite instability (MSI) is a consequence of defi-
cient mismatch repair (dMMR) and serves as a favourable 
prognostic marker for stage II/III CRC [120–122]. However, 
the prevalence of dMMR in mCRC is lower (5%) than in 
the adjuvant setting (around 15%) [123], and data on the 
prognostic and predictive values of MSI in the metastatic 
setting are scarce and conflicting [3, 124, 125]. In the meta-
static setting, MSI-High (H) tumours are associated with 
poor prognosis, although BRAF mutations are more common 
in patients with MSI-H tumours versus those with proficient 
mismatch repair (pMMR) (p < 0.001), which may account 
for this prognosis [126]. While some studies indicate that 
MSI status does not predict the effect of chemotherapy or 
targeted therapy in mCRC [127, 128], a recent randomised 
Phase III trial has found that patients with MSI-H tumours, 
experienced a longer OS when treated with chemotherapy 
plus bevacizumab versus cetuximab (p < 0.001) [129]. Fur-
ther prospective studies are warranted. However, MSI status 
has been shown to be predictive for the use of immuno-
therapy in the treatment of patients with mCRC (Table 1) 
[130]. In a Phase II study designed to evaluate the clinical 
activity of pembrolizumab (programmed cell death ligand 1 
inhibitor), the immune-related objective response rate [40% 
(n = 4/10) vs 0% (n = 0/18)] and 20-week immune-related 
PFS rate [78% (n = 7/9) vs 11% (n = 2/18)] were higher for 
patients with dMMR versus pMMR CRCs [130]. Based on 
such early clinical data, nivolumab and pembrolizumab have 
been approved by the US Food and Drug Administration 
(FDA) for mCRC patients with MSI-H/dMMR disease that 
has progressed following treatment with a fluoropyrimi-
dine, oxaliplatin and irinotecan (Fig. 2) [131, 132]. More 
recently, the FDA approved low-dose ipilimumab in com-
bination with nivolumab for use in these patients based on 
the CheckMate-142 study, which demonstrated that this 
combination produces high response rates, encouraging sur-
vival outcomes and may provide improved efficacy relative 
to immuno-monotherapy (Fig. 2) [133, 134]. MSI testing 
for immune checkpoint inhibitors was included in the most 
recent ESMO guidelines, prior to FDA approval of these 
agents [3].
There is an ongoing need to develop new strategies to 
improve the efficacy of checkpoint inhibitors in microsatel-
lite stable disease. However, the use of combination strate-
gies, such as combining checkpoint inhibitors with MEK 
inhibitors to increase the number of infiltrating effector lym-
phocytes, or anti-angiogenic agents for their immunomodu-
latory properties, have not demonstrated any benefit to date 
[135–137]. Recent data suggest that inactivation of DNA 
repair may provide benefit by increasing the tumour neoan-
tigen burden [138], an approach which has the potential to 
be therapeutically exploited by the use of alkylating agents.
7  Other Emerging Biomarkers for Predicting 
Therapeutic Response in mCRC 
Recent studies have uncovered a number of other potentially 
important biomarkers for predicting therapeutic response 
(Table 2). Tumour mutational load, defined as the number 
of mutations per coding area of a tumour genome, is associ-
ated with MSI/MMR status [139]. Some studies have dem-
onstrated that tumour mutational load may be a predictive 
biomarker for response to chemotherapy and immunotherapy 
in patients with mCRC; however, the data need to be con-
firmed in larger studies [129, 140–142]. The relationship 
between mutations that impair DNA polymerase epsilon 
(POLE) proofreading and tumour immunogenicity have 
been explored. In a retrospective analysis of more than 4500 
patients with stage II/III CRC, the presence of POLE muta-
tions identified a subset of CRC patients with immunogenic 
tumours and very good prognosis [143]. The hypermutated 
phenotype of these tumours suggests that they will be excel-
lent candidates for immunotherapeutic approaches.
Tumours bearing gene fusions, including rearrangements 
in RET, ALK, ROS1, and NTRK1-2-3, may represent rare 
but clinically relevant mCRC subtypes with poor progno-
sis [144, 145]. Targeted strategies inhibiting RET, ALK, 
ROS, and TrkA-B-C have demonstrated encouraging results 
[144–146]; however, mechanisms of resistance may develop 
and mutations have been observed in the catalytic domain of 
receptors [147]. Preliminary evidence suggests these fusions 
may be negative predictive biomarkers for anti-EGFR 
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therapy [144, 145, 148]. Of note, a recent post hoc analysis 
of the VALENTINO study evaluating the PRESSING panel, 
which was created to group rare genomic markers beyond 
RAS/BRAF, including RET, ALK, ROS1, and NTRK1-2-3, 
to predict anti-EGFR resistance [149], found that PRESS-
ING-positive tumours had poorer outcomes compared with 
PRESSING-negative tumours in patients receiving FOL-
FOX plus panitumumab followed by maintenance with 
panitumumab ± 5-FU/leucovorin (PFS 7.7 vs 12.1 months, 
HR 2.07, 95% CI 1.43–2.99; p = 0.0001) [148].
Hypermethylation of CpG islands is frequently observed 
in CRCs, which are then classified as CpG island methylator 
phenotype (CIMP) positive [150, 151]. Contradictory data 
have been reported for the prognostic and predictive role of 
CIMP status in CRC [152–156]. In patients with stage III 
CRC treated with oxaliplatin-based adjuvant chemotherapy, 
CIMP was recently found to be associated with shorter OS 
(HR 1.46, 95% CI 1.02–1.94; p = 0.04) and shorter survival 
after recurrence (HR 1.76, 95% CI 1.20–2.56; p < 0.0004) 
[157]. Interestingly, there was a non-significant trend for 
a possible detrimental effect of cetuximab in patients with 
CIMP-positive tumours [157]. Promoter CpG island hyper-
methylation of O(6)-methylguanine-DNA-methyltrans-
ferase, a DNA repair protein, may predict clinical response 
to alkylating agents although further research is warranted 
[158, 159]. A number of other epigenetic prognostic markers 
have been investigated in CRC [160]. For example, a recent 
prospective study suggests that HPP1 methylation may be 
both a prognostic marker and early marker of response in 
mCRC [161].
Interest is growing in ctDNA as an analyte for evalu-
ating prognosis and early treatment response [162]. For 
example, in addition to being of known prognostic value, 
ctDNA has been proposed as an early marker of response 
to chemotherapy in patients with mCRC [163, 164]. In a 
recent prospective study, patients with a high (> 10 ng/mL) 
versus low (≤ 0.1 ng/mL) ctDNA concentration before ini-
tiating first- or second-line chemotherapy had a shorter OS 
(6.8 vs 33.4 months; adjusted HR 5.64, 95% CI 2.5–12.6; 
p < 0.0001) [164]. Further to this, patients who did not expe-
rience ‘early normalisation’ or an ‘early decrease > 80%’ of 
ctDNA concentration after initiation of treatment experi-
enced less benefit from chemotherapy [164].
Finally, classification/stratification systems for CRC, 
such as consensus molecular subtypes (CMS) and colorectal 
cancer intrinsic subtypes (CRIS), have been proposed [165, 
166]. Both exploit the intrinsic gene signatures specific to 
CRC cells and may have predictive and prognostic value in 
mCRC [165–168]. Specifically, CMS has been shown to be 
prognostic for ORR (p = 0.023), PFS (p < 0.001), and OS 
(p < 0.001) [167], and a recent small retrospective study sug-
gests that it is also predictive for the efficacy of chemother-
apy in mCRC [168]. Further to this, CRIS has been shown to 
predict response to EGFR-targeting antibodies and to predict 
disease outcome independently of clinical stage and stromal 
infiltration [166].
8  Ongoing Molecular‑Guided Clinical Trials
Several molecular-guided clinical trials in mCRC are under-
way (Table 3). FOCUS4, which began recruitment in 2014, 
is an integrated programme of parallel, molecularly strati-
fied, randomised comparisons for patients with advanced 
or mCRC [169]. It is derived from a multi-arm, multi-stage 
design to be adjustable should new biomarker and clinical 
data arise during the trial, while being cost and time effi-
cient. In this programme, novel agents are tested in patient 
populations defined by whether their tumours harbour muta-
tions in BRAF, PIK3CA, RAS, and TP53 or are MSI/dMMR. 
Its multi-stage design provides an early efficacy signal of the 
new agents being assessed through a series of pre-planned 
interim analyses [169]. Other ongoing molecular-guided tri-
als include a Phase III study investigating pembrolizumab 
versus standard-of-care chemotherapy as first-line therapy 
for dMMR or MSI-H mCRC (NCT02563002), and Phase 
II studies investigating atezolizumab and bevacizumab in 
patients with unresectable mCRC and MSI (NCT02982694), 
anti-EGFR therapy in mCRC patients with low or high 
ERCC1 (NCT01703390), treatment with HER2 mono-
clonal antibodies in HER2-amplified advanced or mCRC 
(NCT03365882), and Sym004 treatment in chemotherapy-
refractory mCRC patients with acquired resistance to anti-
EGFR therapy (NCT03549338).
Other clinical trials are exploring re-challenge with anti-
EGFR therapy. Dynamic clonal competition leads to a rise in 
anti-EGFR-resistant mutant clones during anti-EGFR ther-
apy and a decline upon withdrawal of anti-EGFR antibodies 
[170, 171]. A recent study found that, after discontinuation 
of anti-EGFR therapy, RAS and EGFR clones exponentially 
decayed with an estimated half-life of 3.4 and 6.9 months, 
respectively [171]. These observations provide a molecular 
rationale for studies that have proposed re-challenge with 
cetuximab [172–174] or panitumumab [175, 176], after a 
previous response to anti-EGFR therapy and may help guide 
timing of re-challenge therapies. Recent results from the 
CRICKET trial indicate that re-challenge with cetuximab 
following acquired resistance is more efficient in patients 
without RAS mutations assessed by ctDNA [177]. These 
first results suggest that monitoring tumour sensitivity to 
anti-EGFR agents by iterative ctDNA assessments may 
soon form part of our daily practice. Additional studies 
(CHRONOS, NCT03227926; RASINTRO, NCT03259009; 
FIRE-4, NCT02934529; A-REPEAT, NCT03311750) are 
investigating different challenge strategies using anti-EGFR 
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therapy based on liquid biopsy assessment of dynamic RAS 
clones.
9  Concluding Remarks
Current guidelines regarding biomarkers recommend rou-
tinely making treatment decisions based on RAS, BRAF, 
or MSI status. In this review, we highlight several other 
molecular and non-molecular biomarkers that are undergo-
ing clinical testing and we describe their possible clinical 
relevance (Table 4) as well as highlighting possible treat-
ment strategies according to biomarker status (Fig. 2). For 
example, DPYD genotyping/phenotyping may soon become 
a standard of care to individualise 5-FU chemotherapy dos-
ing. Furthermore, in addition to assessment of BRAF V600E 
mutations, assessment of HER2 amplification may be useful 
to inform physicians of their patients’ prognosis and to guide 
enrolment of patients into ongoing clinical trials dedicated to 
these rare subgroups. Knowledge of prognostic factors can 
be used in clinical decision making to determine the goal of 
treatment and to tailor treatment, for example the selection 
of adjuvant therapy or level of treatment intensity [3, 178]. 
Plasma analysis of ctDNA shows promise as a minimally 
invasive and sensitive method to monitor patient response, 
including acquired resistance to anti-EGFR agents. How-
ever, its utility has to be confirmed and crucially, simple 
assessment tools and positive controls are required for daily 
use, before ctDNA testing can become standard practice. 
Of note, recent studies highlight the use of serial plasma 
biopsies to assess tumour heterogeneity to further inform 
treatment decisions [179, 180].
Further clinical validation of many of the biomarkers 
reviewed here is still required. However, validation and 
translation of new biomarkers into clinical practice is a 
complex process involving a number of steps, each with 
its own set of challenges [181]. Many biomarkers are vali-
dated retrospectively, yet such studies can be affected by 
multiple sources of bias [181]. Thus large-scale prospec-
tive trials with well-defined protocols are needed to further 
identify, develop, and validate biomarkers, to standardise 
their use in clinical practice and inform treatment options 
[2, 8]. However, these are costly and time consuming [181]. 
Employing prospective–retrospective study designs [182] or 
using biobanks from randomised trials [183] provide alter-
native options for biomarker discovery [181], and validating 
molecular-guided clinical trials, including those utilising a 
multi-arm, multi-stage design for cost and time efficiency, 
are underway. Of note, the interaction between biomarkers 
is also likely to be clinically relevant and network biomark-
ers may provide further prognostic and predictive insight in 
the future [184].
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The Evolving Biomarker Landscape in mCRC 
Overall, we are optimistic that the continued prospec-
tive validation of biomarkers along with further develop-
ments in patient molecular profiling technologies will help 
to achieve the goal of true individualised therapy for patients 
with mCRC.
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Table 4  An overview of the potential clinical relevance of the evolving molecular biomarker landscape in mCRC 
BRAF B-rapidly accelerated fibrosarcoma, CIMP CpG island methylator phenotype, CMS consensus molecular subtypes, CRC colorectal cancer, 
CRIS colorectal cancer intrinsic subtypes, DPD dihydropyrimidine dehydrogenase, DPYD DPD gene, EGFR epidermal growth factor receptor, 
ERCC1 excision repair cross-complementation group 1, HER human epidermal growth factor, KRAS Kirsten rat sarcoma viral oncogene, mCRC 
metastatic colorectal cancer, MSI microsatellite instability, NRAS neuroblastoma RAS, PIK3CA phosphatidylinositol 3-kinase catalytic subunit 
alpha, PTEN phosphatase and tensin homolog, RAS rat sarcoma, TS thymidylate transferase, UGT1A1 UDP glucuronosyltransferase 1 family, 
polypeptide A1
a I, currently clinically relevant; II, likely to be clinically relevant soon; III may be clinically relevant in the future; IV, not clinically relevant
Biomarker Clinical 
 relevancea
Biomarker type Clinical implications
DPD (DPYD) I Predictive See Table 1 for current guidance. Testing before fluoropy-
rimidine administration is not routinely recommended. 
However, some European countries currently recommend 
genotype-guided individualised dosing and this may 
become increasingly universally utilised in the clinic
UGT1A1 I Predictive See Table 1 for current guidance
RAS (KRAS, NRAS) I Predictive See Table 1 for current guidance
MSI I Predictive and prognostic See Table 1 for current guidance
BRAF II Prognostic; predictive value to be confirmed See Table 1 for current guidance
CMS III Predictive and prognostic CMS has been shown to be prognostic for response and sur-
vival outcomes and predictive for chemotherapy efficacy
CRIS III Predictive CRIS has been shown to predict response to anti-EGFR 
therapy
HER2 II Predictive; prognostic value to be confirmed Alterations in this gene have been associated with poorer 
survival outcomes. HER2 may become a valuable 
therapeutic target in mCRC; dual HER2-targeted therapy 
has demonstrated efficacy
EGFR III Predictive See Table 1 for current guidance
HER3 III Predictive High HER3 expression is predictive of anti-EGFR therapy 
benefit
microRNA III Predictive A number of microRNAs have been identified as promising 
predictive biomarkers for anti-EGFR therapy
Anti-angiogenic markers III Predictive Many markers have been identified as predictive for 
response to anti-angiogenic agents; however, their clinical 
utility needs to be confirmed in large prospective trials
Tumour mutational load III Predictive; prognostic value to be confirmed Tumour mutational load may be a predictive biomarker for 
response to chemotherapy and immunotherapy
Gene fusions (RET/
ALK/ROS1/NTRK)
III Predictive and prognostic Preliminary evidence suggests that rare gene fusions may 
be negative predictive biomarkers for anti-EGFR therapy. 
Targeted strategies inhibiting RET, ALK, ROS and TrkA-
B-C have demonstrated encouraging results
CIMP III Predictive and prognostic to be confirmed Data for the prognostic and predictive role of CIMP status 
in CRC are currently contradictory
HPP1 methylation IV Prognostic Detection of HPP1 methylation before chemotherapy has 
been associated with poor survival outcomes
TS IV – See Table 1 for current guidance
ERCC1 IV – See Table 1 for current guidance
PIK3CA IV – See Table 1 for current guidance
PTEN IV _ See Table 1 for current guidance
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